ProCE Banner Activity

Key HIV Studies Influencing My Practice Following CROI 2022

Slideset Download
Conference Coverage
Read expert faculty members’ summaries of key HIV studies from CROI 2022, including results from studies of prevention strategies, long-acting therapies, second-line therapies, comorbidities, and cure.

Released: March 02, 2022

Expiration: March 01, 2023

No longer available for credit.

Share

Faculty

Monica Gandhi

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Daniel R. Kuritzkes

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

David A. Wohl

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Cepheid

Gilead Sciences, Inc.

Janssen Therapeutics Division of Janssen Products

Merck & Co., Inc.

ViiV Healthcare

Faculty Disclosure

Primary Author

Monica Gandhi, MD, MPH

Professor of Medicine
Division of HIV, Infectious Diseases, and Global Medicine
Medical Director, Ward 86 HIV Clinic
University of California, San Francisco
San Francisco, California

Monica Gandhi, MD, MPH, has no relevant conflicts of interest to report.

Daniel R. Kuritzkes, 医学博士

科长,传染病科
布莱根妇女医院
Harriet Ryan Albee 医学教授
哈佛医学院
波士顿,马萨诸塞州

Daniel R. Kuritzkes, MD, has reported that he has received funds for research support from Gilead Sciences, Merck, and ViiV Healthcare and consulting fees from Abpro, Atea, Decoy, Gilead Sciences, GlaxoSmithKline, Janssen, Merck, ViiV Healthcare, and ViroStatics.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consulting fees from Gilead Sciences, Merck, and ViiV Healthcare/GSK and funds for independent contractor from Johnson & Johnson.

David A. Wohl, MD

Professor of Medicine
School of Medicine
Site Leader, Global Clinical Trials Unit-Chapel Hill
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

David A. Wohl, MD, has disclosed that he has received funds for research support from Gilead Sciences and Merck and consulting fees from Gilead Sciences, Janssen, Merck, and ViiV.